Pancreatic Cancer Research

ResearcherInstitut d'Investigació Biomédica de BellvitgeActive in the last 2 years

Juli Busquets

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6685-3135; OpenAlex author ID A5073647085. Sources: ClinicalTrials.gov.

Their work

Papers
10 (first author 2, last author 0)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
43
Papers, trials and grants by year

2013: 1 trial · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 3 papers · 2025: none · 2026: 4 papers

Papers 10

  1. Consensus-based validation of key quality indicators in pancreatic cancer surgery in Catalonia: a modified Delphi study. Co-author DOI 10.1016/j.cireng.2026.800304↗
  2. Technical options in the occlusion of the superior mesenteric vein for locally advanced pancreatic cancer. Co-author DOI 10.1016/j.cireng.2026.800395↗
  3. A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With N… Co-author DOI 10.1097/coc.0000000000001253↗
  4. Futility in adenosquamous pancreatic cancer. Co-author DOI 10.1186/s12957-026-04351-1↗
  5. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives. Co-author DOI 10.1007/s13304-024-01860-0↗
  6. The involvement of the hepatic artery is a risk factor for unresectability after neoadjuvant treatment in borderline pancreatic adenocarcinoma. First author DOI 10.1016/j.suronc.2023.102027↗
  7. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  8. Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospect… First author DOI 10.1097/md.0000000000032126↗
  9. Expression and Role of MicroRNAs from the miR-200 Family in the Tumor Formation and Metastatic Propensity of Pancreatic Cancer. Co-author DOI 10.1016/j.omtn.2019.06.015↗
  10. Initial Experience in the Treatment of "Borderline Resectable" Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.ciresp.2017.07.008↗

Trials 1

  1. Billroth II or Roux-en-Y Reconstruction for GJ After PD: Randomized Controlled Trial (PAUDA TRIAL) Principal investigator NCT02246205↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Berta Laquente · 4 shared papers, 2017–2026 · strength 0.71
  2. Juan Fabregat · 3 shared papers, 2017–2024 · strength 0.46
  3. Lluís Secanella · 3 shared papers, 2017–2024 · strength 0.46
  4. Santiago Sánchez-Cabús · 2 shared papers, 2026 · strength 0.42
  5. Elizabeth Pando · 2 shared papers, 2026 · strength 0.42
  6. Fernando Burdı́o · 2 shared papers, 2026 · strength 0.42
  7. Elena Iborra Ortega · 1 shared paper, 2026 · strength 0.39
  8. Luis Secanella · 1 shared paper, 2026 · strength 0.39
  9. Rafael Álvarez-Gallego · 1 shared paper, 2026 · strength 0.25
  10. Florian Castet · 1 shared paper, 2026 · strength 0.25
  11. Yolanda Quijano · 1 shared paper, 2026 · strength 0.25
  12. Emilio Vicente · 1 shared paper, 2026 · strength 0.25
  13. Antonio Cubillo · 1 shared paper, 2026 · strength 0.25
  14. Teresa Mercade Macarulla · 1 shared paper, 2026 · strength 0.25
  15. Laura Guarga · 1 shared paper, 2026 · strength 0.24
  16. Fabio Ausania · 1 shared paper, 2026 · strength 0.24
  17. Paula Manchon‐Walsh · 1 shared paper, 2026 · strength 0.24
  18. Patricia Sánchez‐Velázquez · 1 shared paper, 2026 · strength 0.24
  19. Cristina Vallejo Bernad · 1 shared paper, 2026 · strength 0.18
  20. Julie Navez · 1 shared paper, 2026 · strength 0.18
  21. Bodil Andersson · 1 shared paper, 2026 · strength 0.18
  22. Bergþór Björnsson · 1 shared paper, 2026 · strength 0.18
  23. Sebastian Manuel Staubli · 1 shared paper, 2026 · strength 0.18
  24. Dimitrios E. Giakoustidis · 1 shared paper, 2026 · strength 0.18
  25. Gennaro Nappo · 1 shared paper, 2026 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.